Innovative drugs enter a period of intensive data-driven catalysis, and the Ping An Medical Innovation ETF is receiving widespread attention.

Ask AI · How does the Ping An Healthcare Innovation ETF benefit from industry growth trends?

As of 11:10 on April 3, 2026, the components of the CSI Medicine and Medical Devices Innovation Index(931484) showed mixed gains and losses, with InnoCare Medical leading up 1.81%, Sinopharm Chemical increased 1.45%, and San Sheng Guo Jian up 0.98%; new industry leaders declined. The Ping An Healthcare Innovation ETF(516820) latest quote is 0.36 yuan.

In terms of liquidity, the Ping An Healthcare Innovation ETF had a turnover rate of 2.14% during the trading session, with a transaction volume of 38.4706 million yuan. Looking at a longer period, as of April 2, the average daily trading volume of the Ping An Healthcare Innovation ETF over the past week was 66.9685 million yuan.

Revenue from innovative drugs is growing strongly. As of March 29, more than 70 biopharmaceutical companies have released their 2025 performance forecasts. Among them, 61 companies are profitable, accounting for nearly 90%; 29 companies have achieved positive year-over-year net profit attributable to parent company (excluding losses), with 7 companies doubling their performance. Additionally, companies like Rongchang Biotech, Nuocheng Jianhua, and Digital Human are expected to turn losses into profits, while Mengke Pharmaceutical, Junshi Biosciences, and Maiwei Biotech have reduced losses year-over-year.

CITIC Securities research reports indicate that since 2026, the transaction volume of China’s innovative drug business development (BD) deals has exceeded expectations, further enhancing the industry’s global competitiveness; the domestic market is rapidly expanding. According to the 2025 annual report, leading innovative drug companies are experiencing rapid revenue growth driven by new products, with biopharma companies gradually reaching profitability inflection points; upcoming international academic conferences will bring a surge of data on many innovative drug pipelines. In summary, the global value of the innovative drug industry is highlighted, entering a period of intensive data-driven catalysts. It is recommended to focus on: 1. Leading innovative drug companies are expected to release performance; 2. Core pipelines are about to see major data readouts; 3. Pipeline assets with global potential may accelerate internationalization.

The Ping An Healthcare Innovation ETF closely tracks the CSI Medicine and Medical Devices Innovation Index. This index selects 30 listed companies from the healthcare industry with good profitability, certain growth potential, and R&D capabilities as its sample, reflecting the overall performance of profitable and growing pharmaceutical and medical device companies.

Data shows that as of March 31, 2026, the top ten holdings of the CSI Medicine and Medical Devices Innovation Index(931484) are WuXi AppTec, Hengrui Medicine, Mindray Medical, Sinopharm Chemical, Pianzihuang, Aier Eye Hospital, Huadong Medicine, Kanglong Chemical, InnoCare Medical, and Erythropoietin, with the top ten holdings accounting for 63.82% of the total.

Risk reminder: Funds carry risks; investment should be cautious. The fund manager commits to managing and using the fund assets honestly, diligently, and responsibly but does not guarantee profits or minimum returns. Investors are reminded that fund investments are based on the “buyer bears the risk” principle. After making an investment decision, any risks arising from the fund’s operation and net asset value fluctuations are borne by the investor. Past performance and net asset value do not predict future results, and the performance of other funds managed by the fund manager does not guarantee this fund’s performance. Investors may share in the fund’s investment returns or bear losses. Investors should carefully read the fund contract, prospectus, and other legal documents to fully understand the risk-return profile and characteristics of the fund, and assess whether it matches their investment objectives, time horizon, experience, and asset situation. Make rational market judgments and cautious investment decisions. The information provided here is sourced from publicly available data deemed reliable by the fund manager; opinions, assessments, and forecasts reflect current judgments and may change later. Any market views are based on assumptions, which may change at any time. The fund manager does not promise or guarantee that any predictive market view will necessarily materialize. The stocks mentioned do not constitute investment recommendations or advice. The secondary market fluctuations of ETF share prices do not represent the actual returns of the fund; investors should be aware of intraday price volatility risks.